You just read:

Akcea Announces Approval for Reimbursement of TEGSEDI® (inotersen) in Spain for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy

News provided by

Akcea Therapeutics, Inc.

14 May, 2020, 21:05 BST